EquitySector - HealthcareVery High Risk
Direct
NAV (20-Feb-25)
Returns (Since Inception)
Fund Size
₹3,198 Cr
Expense Ratio
0.58%
ISIN
INF740KA1LG1
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
30 Nov 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+16.81%
+12.48% (Cat Avg.)
3 Years
+22.84%
+18.71% (Cat Avg.)
5 Years
+26.84%
+23.12% (Cat Avg.)
Since Inception
+25.75%
— (Cat Avg.)
Equity | ₹3,172.08 Cr | 99.20% |
Others | ₹25.44 Cr | 0.80% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹327.07 Cr | 10.23% |
Cipla Ltd | Equity | ₹264.88 Cr | 8.28% |
Suven Pharmaceuticals Ltd | Equity | ₹262.58 Cr | 8.21% |
Ipca Laboratories Ltd | Equity | ₹231.5 Cr | 7.24% |
Globus Medical Inc Class A | Equity | ₹215.93 Cr | 6.75% |
Illumina Inc | Equity | ₹184.47 Cr | 5.77% |
Gland Pharma Ltd | Equity | ₹140.38 Cr | 4.39% |
Apollo Hospitals Enterprise Ltd | Equity | ₹132.65 Cr | 4.15% |
Laurus Labs Ltd | Equity | ₹131.72 Cr | 4.12% |
Alembic Pharmaceuticals Ltd | Equity | ₹130.99 Cr | 4.10% |
Concord Biotech Ltd | Equity | ₹125.82 Cr | 3.94% |
Vijaya Diagnostic Centre Ltd | Equity | ₹105.45 Cr | 3.30% |
Sai Life Sciences Ltd | Equity | ₹104.9 Cr | 3.28% |
Intuitive Surgical Inc | Equity | ₹92.99 Cr | 2.91% |
Kovai Medical Center & Hospital Ltd | Equity | ₹90.53 Cr | 2.83% |
Pfizer Ltd | Equity | ₹90.24 Cr | 2.82% |
Procter & Gamble Health Ltd | Equity | ₹85.42 Cr | 2.67% |
Indoco Remedies Ltd | Equity | ₹80.82 Cr | 2.53% |
Unichem Laboratories Ltd | Equity | ₹51.98 Cr | 1.63% |
ICICI Lombard General Insurance Co Ltd | Equity | ₹44.87 Cr | 1.40% |
Narayana Hrudayalaya Ltd | Equity | ₹44.55 Cr | 1.39% |
Emcure Pharmaceuticals Ltd | Equity | ₹42.11 Cr | 1.32% |
Abbott Laboratories | Equity | ₹35.03 Cr | 1.10% |
Aarti Drugs Ltd | Equity | ₹34.01 Cr | 1.06% |
Treps / Reverse Repo Investments | Cash - Repurchase Agreement | ₹29.61 Cr | 0.93% |
Global X Genomics & Biotechnology ETF | Mutual Fund - ETF | ₹21.61 Cr | 0.68% |
Alkem Laboratories Ltd | Equity | ₹18.9 Cr | 0.59% |
Thyrocare Technologies Ltd | Equity | ₹18.29 Cr | 0.57% |
Lupin Ltd | Equity | ₹16.67 Cr | 0.52% |
Jupiter Life Line Hospitals Ltd | Equity | ₹15.72 Cr | 0.49% |
Medplus Health Services Ltd | Equity | ₹13.89 Cr | 0.43% |
Laxmi Dental Ltd | Equity | ₹13.85 Cr | 0.43% |
Net Receivables/Payables | Cash | ₹-4.23 Cr | 0.13% |
GRAIL Inc | Equity | ₹2.29 Cr | 0.07% |
Large Cap Stocks
18.51%
Mid Cap Stocks
13.90%
Small Cap Stocks
49.08%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹3,105.66 Cr | 97.13% |
Financial Services | ₹44.87 Cr | 1.40% |
Standard Deviation
This fund
15.15%
Cat. avg.
15.76%
Lower the better
Sharpe Ratio
This fund
1.04
Cat. avg.
0.85
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.56
Higher the better
Since December 2020
ISIN INF740KA1LG1 | Expense Ratio 0.58% | Exit Load No Charges | Fund Size ₹3,198 Cr | Age 6 years 2 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹27.99 Cr | 11.6% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.1% | 1.0% | ₹815.09 Cr | 6.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹815.09 Cr | 4.8% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹41.19 Cr | 9.0% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹216.51 Cr | 11.9% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹216.51 Cr | 9.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹2652.24 Cr | 12.3% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2652.24 Cr | 10.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹866.14 Cr | 8.2% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.92 Cr | 8.9% |
Total AUM
₹1,87,362 Cr
Address
West Wing, 11th Floor, Mumbai, 400021
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (20-Feb-25)
Returns (Since Inception)
Fund Size
₹3,198 Cr
Expense Ratio
0.58%
ISIN
INF740KA1LG1
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
30 Nov 2018
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+16.81%
+12.48% (Cat Avg.)
3 Years
+22.84%
+18.71% (Cat Avg.)
5 Years
+26.84%
+23.12% (Cat Avg.)
Since Inception
+25.75%
— (Cat Avg.)
Equity | ₹3,172.08 Cr | 99.20% |
Others | ₹25.44 Cr | 0.80% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹327.07 Cr | 10.23% |
Cipla Ltd | Equity | ₹264.88 Cr | 8.28% |
Suven Pharmaceuticals Ltd | Equity | ₹262.58 Cr | 8.21% |
Ipca Laboratories Ltd | Equity | ₹231.5 Cr | 7.24% |
Globus Medical Inc Class A | Equity | ₹215.93 Cr | 6.75% |
Illumina Inc | Equity | ₹184.47 Cr | 5.77% |
Gland Pharma Ltd | Equity | ₹140.38 Cr | 4.39% |
Apollo Hospitals Enterprise Ltd | Equity | ₹132.65 Cr | 4.15% |
Laurus Labs Ltd | Equity | ₹131.72 Cr | 4.12% |
Alembic Pharmaceuticals Ltd | Equity | ₹130.99 Cr | 4.10% |
Concord Biotech Ltd | Equity | ₹125.82 Cr | 3.94% |
Vijaya Diagnostic Centre Ltd | Equity | ₹105.45 Cr | 3.30% |
Sai Life Sciences Ltd | Equity | ₹104.9 Cr | 3.28% |
Intuitive Surgical Inc | Equity | ₹92.99 Cr | 2.91% |
Kovai Medical Center & Hospital Ltd | Equity | ₹90.53 Cr | 2.83% |
Pfizer Ltd | Equity | ₹90.24 Cr | 2.82% |
Procter & Gamble Health Ltd | Equity | ₹85.42 Cr | 2.67% |
Indoco Remedies Ltd | Equity | ₹80.82 Cr | 2.53% |
Unichem Laboratories Ltd | Equity | ₹51.98 Cr | 1.63% |
ICICI Lombard General Insurance Co Ltd | Equity | ₹44.87 Cr | 1.40% |
Narayana Hrudayalaya Ltd | Equity | ₹44.55 Cr | 1.39% |
Emcure Pharmaceuticals Ltd | Equity | ₹42.11 Cr | 1.32% |
Abbott Laboratories | Equity | ₹35.03 Cr | 1.10% |
Aarti Drugs Ltd | Equity | ₹34.01 Cr | 1.06% |
Treps / Reverse Repo Investments | Cash - Repurchase Agreement | ₹29.61 Cr | 0.93% |
Global X Genomics & Biotechnology ETF | Mutual Fund - ETF | ₹21.61 Cr | 0.68% |
Alkem Laboratories Ltd | Equity | ₹18.9 Cr | 0.59% |
Thyrocare Technologies Ltd | Equity | ₹18.29 Cr | 0.57% |
Lupin Ltd | Equity | ₹16.67 Cr | 0.52% |
Jupiter Life Line Hospitals Ltd | Equity | ₹15.72 Cr | 0.49% |
Medplus Health Services Ltd | Equity | ₹13.89 Cr | 0.43% |
Laxmi Dental Ltd | Equity | ₹13.85 Cr | 0.43% |
Net Receivables/Payables | Cash | ₹-4.23 Cr | 0.13% |
GRAIL Inc | Equity | ₹2.29 Cr | 0.07% |
Large Cap Stocks
18.51%
Mid Cap Stocks
13.90%
Small Cap Stocks
49.08%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹3,105.66 Cr | 97.13% |
Financial Services | ₹44.87 Cr | 1.40% |
Standard Deviation
This fund
15.15%
Cat. avg.
15.76%
Lower the better
Sharpe Ratio
This fund
1.04
Cat. avg.
0.85
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.56
Higher the better
Since December 2020
ISIN INF740KA1LG1 | Expense Ratio 0.58% | Exit Load No Charges | Fund Size ₹3,198 Cr | Age 6 years 2 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹27.99 Cr | 11.6% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.1% | 1.0% | ₹815.09 Cr | 6.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹815.09 Cr | 4.8% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹41.19 Cr | 9.0% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹216.51 Cr | 11.9% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹216.51 Cr | 9.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹2652.24 Cr | 12.3% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2652.24 Cr | 10.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹866.14 Cr | 8.2% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.92 Cr | 8.9% |
Total AUM
₹1,87,362 Cr
Address
West Wing, 11th Floor, Mumbai, 400021
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments